Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 6/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8230136 | 0.93 | CTSL (0.51) | CTSLCTSSTGM2SIRT2SIRT1 | |
| SCHEMBL10035707 | 0.91 | TGM2 (0.59) | TGM2 | |
| SCHEMBL10035709 | 0.87 | SYK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL8230194 | 0.84 | TGM2 (0.58) | CTSLCTSSTGM2 | |
| SCHEMBL10035721 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL27649586 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSCAPN1PSMB8 | |
| SCHEMBL10035700 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSSIRT2SIRT1 | |
| SCHEMBL6384766 | 0.83 | CTSK (0.55) | CTSKCTSLCTSSCAPN1PSMB8 | |
| SCHEMBL9293333 | 0.81 | FOLH1 (0.68) | TGM2SIRT2SIRT1 | |
| SCHEMBL18095595 | 0.81 | SYK (0.54) | CTSKTGM2SIRT2SIRT1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | CTSK 98/4885CTSL 836/4885CTSS 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.